mellitus are relatively weak, with odds ratios below 1.2 (23), PPAR gamma is the target of thiazolidinediones, a class of oral antidiabetic agents (24). Another striking example is the LDL receptor where, while mutations only account for a small fraction of hyperlipidemias their discovery has been instrumental to the development, and our understanding of the mechanism of action, of statins that revolutionized hyperlipidemia treatment (25).
